Treats infection caused by various strains of influenza A virus. ANDA 76186, held by Upsher-Smith Laboratories. Amantadine Hydrochloride.
As of Nov 21, 2026, ANDA 76186 (Amantadine Hydrochloride), held by Upsher-Smith Laboratories, was first approved by FDA on Dec 16, 2002, with 6 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Amantadine hydrochloride tablets are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride tablets are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride tablets are indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 16, 2002 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Amantadine Hydrochloride100MG · tablet;oral | Amantadine Hydrochloride | Rx |
| Jul 10, 2025 | Supplement 31Labeling · Standard review | Approved | None posted |
| Dec 13, 2017 | Supplement 22Manufacturing | Approved | None posted |
| Jan 18, 2012 | Supplement 18Labeling | Approved | None posted |
| Jun 4, 2009 | Supplement 12Labeling | Approved | None posted |
| Feb 9, 2009 | Supplement 10Labeling | Approved | None posted |
| Nov 19, 2007 | Supplement 9Labeling | Approved | None posted |
| Dec 16, 2002 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters